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ABSTRACT
Objective: This study aims to show the effect of myeloperoxidase (MPO), hsCRP, TNF-alpha values and leukocyte count on the development of 
coronary collateral arteries in patients with severely diseased coronary arteries.
Methods: Current study is an observational cross-sectional study. In the study, 295 patients who had functional obstruction or total coronary 
occlusion at least 1 month on their angiograms were included. We divided the study population into two groups according to their collateral 
grade as good collateral (Group 1) (169 patients) and poor collateral (Group 2) (126 patients). Multiple logistic regression analysis was used for 
independent variables associated with the coronary collateral grade.
Results: History of stable angina pectoris was statistically more prevalent in good collateral group (61.5% and 48.4%, p=0.025). Furthermore, 
MPO activation was higher in good collateral group and the difference was statistically significant (3.7 U/mL and 3.0 U/mL p=0.001). In multiple 
logistic regression analysis, stable angina pectoris [OR 1.7, 95% CI (1.05-2.8), p=0.03] and high MPO levels [OR 2.7, 95% CI (1.7-4.3), p<0.001] were 
found to be independent predictors of good collateral development.
Conclusion: We think that proinflammatory enzymes and cytokines released from these cells rather than inflammatory cells themselves may 
play an important role on the collateral development. (Anadolu Kardiyol Derg 2014; 14: 336-41)
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Introduction
Atherosclerotic heart disease is the most frequent cause of 
death in adults. Recent advances in the modernization of 
coronary intensive care units, the use of beta blockers, coronary 
bypass surgery, fibrinolytic therapy and primary coronary 
angioplasty and similar treatment methods has resulted in 
important declines in mortality rates due to coronary heart 
disease (1, 2). A well-developed collateral artery also restricts 
the infarction area during acute myocardial infarction (MI) and 
prevents the occurrence of Q wave MI, left ventricular aneurysm 
and coronary failure. As is known, inflammation has a significant 
role in the progression of atherosclerosis. For this reason, an 
examination of inflammatory markers that can affect the 
development of collateral arteries is important (2-7).
The imbalance between oxygen requirements as a result of 
coronary artery stenosis or coronary artery occlusion lead to an 
increase in coronary collateral development in humans, dogs 
and pigs. The formation of coronary collaterals takes the form of 
de novo “angiogenesis” with the budding of new capillaries in 
existing blood vessels or as “arteriogenesis” that is present as 
a result of the development and maturing of anastomosis 
vessels in existing arteries since birth (6). In both cases 
endothelial cells and the growth factors secreted from 
inflammatory cells such as thrombocyte and monocyte that 
attack the ischemic region play an important role (6-8).
The tumor necrosis factor b (TNF-alfa) is a proinflammatory 
cytokine that is produced from leading macrophages. It increases 
the expression of adhesion molecules (such as VCAM-1 and 
ICAM-1). And also by increasing the production of nitric oxide 
(NO) and prostacycline from endothelium, it increases blood 
flow and creates local vasodilatation (9-14).
CRP is one of the marker of vascular inflammation. Some 
studies show inverse graded association between CRP and the 
presence of coronary collaterals in patients with stable angina 
pectoris (15-18). In our study there is no relation between hsCRP 
and collateral development. White blood cells are one of the 
important cells that give response to inflammation. Widely used, 
stable and with better standardization compared to other 
inflammatory indicators, white blood cell measurement is 
considered as an independent predictor of smoking, age etc. in 
cardiovascular mortality (19).
Myeloperoxidase (MPO) is stored inside azurophilic granules 
within polymorphic nuclei neutrophils and macrophages (20). 
MPO, through hydrogen peroxide reaction, forms permeable 
oxidative substances that contains free radicals, antimicrobial 
activities and causes oxidative damage in tissues (20-23). It is 
elevated in coronary artery disease and higher levels of MPO is 
found with progression of coronary artery disease (CAD) (21).
It has been shown that TNF-alfa and through nitric acid 
oxide synthesis of high sensitive C-reactive protein (hsCRP), 
cytokines and development factors regulates angiogenesis (12). 
But there is no sufficient data in the relationship between MPO, 
white cells and collateral development. There are interindividual 
differences in the number and extent of collateral vessels 
among patients with a similiar degree of coronary atherosclerosis 
(4). This is due to environmental and genetic disparities. In this 
study, we have aimed in identifying the inflammatory markers 
such as MPO serum, TNF-alfa, hsCRP and white blood cell count 
which we consider to effect the collateral development.
Methods
Study design
This study has a cross-sectional and observational design.
Study population
The study population consisted of 295 patients who 
underwent clinically indicated coronary angiography in our 
department and were found to have at least one major coronary 
occlusion, or a stenosis of ≥95% with Thrombolysis In Myocardial 
Infarction (TIMI) grade ≤1 anterograde flow between October 
2008 and April 2009. All patients had stable anginal symptoms 
and/or positive stress test results or electrocardiographic 
changes indicating ischemia.
Study protocol
Clinical characteristics of the patients including age, weight, 
gender and any data known to influence development of 
collaterals such as current medications, history of hypertension, 
diabetes mellitus, complete blood count and fasting glucose 
levels were documented. Patients with a history of coronary 
bypass surgery were excluded if the operation has been done 
within the past 30 days and the distal aspect of the qualifying 
severly stenosed or occluded artery is supplied by the patent 
bypass greft. Patients who had percutaneous coronary 
intervention within 30 days, acute or chronic infectious disease 
and malignancy were also excluded. All patients gave written 
informed consent and local Ethics Commitee approved the study 
protocol.
Baseline clinical examination
Routine blood samples were taken from the patients who 
were admitted to hospital for coronary angiography after 
overnight fasting. Patients with low density lipoprotein (LDL) 
levels greater than 100 mg/dL or under lipid lowering drug 
therapy were considered to have hyperlipidemia. Patients with 
systolic or diastolic blood pressure ≥140 mm Hg or 90 mm Hg or 
who were under antihypertensive treatment were considered to 
be hypertensive (based on the mean of the two readings). 
Patients who were being treated for diabetes mellitus (DM) or 
who had a fasting glucose concentration ≥126 mg/dL were 
considered to have DM. Smoking habit was recorded as one 
that has lasted for more than 1 year. The Friedewald’s formula 
was used for LDL cholesterol measurement.
Laboratory analyses
5 mL of blood samples were collected from the arterial 
sheaths immediately following coronary angiography from each 
patient and vacutiner tubes centrifuged at 5000 rpm for 15 
minutes within 1 hour. Then plasma collected and stored at 
-20˚C. MPO was measured with enzyme linked immunosorbent 
assay (ELISA) (Imtec MPO ANCA. Wiesbaden-Germany) and 
TNF-alpha was measured with ELISA (Biosource, Carlsbad, 
California, USA) in immunology laboratuary. hsCRP was 
measured with nephelometry (CardioPhase hsCRP, BN II 
nefelometre, Dade- Behring-Germany) and white blood cell 
counts were measured in the Beckman Coulter LH 750 automotic 
blood count analyzer by the VSC prinsible in Ankara University 
İbni-Sina hospital central laboratuary.
Coronary angiography and grading of coronary collaterals 
Coronary angiography was completed by two experienced 
cardiologist blinded to the study (Philips Integris 3000 system 
Philips, Holland) according to the Judkins technique using 
automated quantitative coronary artery stenosis assessment 
program of same system. The diseased vessel was identified as 
stenosis of the major coronary artery of at least 75%. Collateral 
flow was graded according to the Rentrop classification (6) and 
based on the injection that best opacified the occluded vessel: 
grade 0, no visible filling of any collateral vessels; grade 1, filling 
of side branches of the artery to be perfused by collateral 
vessels without visualization of the epicardial segment; grade 2, 
partial filling of the epicardial segment by collateral vessels; and 
grade 3, complete filling of the epicardial segment by collateral 
vessels. According to this classification we divided 295 patients 
into two groups. Grade 0 and 1 were named as poor collateral 
(Group 2), grade 2 and 3 were named as good collateral (Group 1). 
In subjects with >1 collateral supplying the distal aspect of the 
diseased artery, the higher collateral grade was used. In 
subjects with >1 qualifying severly diseased vessel, the vessel 
with the higher collateral grade was chosen for analysis.
Statistical analysis
Categorical variables were defined as percentage, continuous 
variables were presented as mean±standard error. Comparisons 
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among groups were tested for normal distribution with student-t 
test, for abnormal distribution with Mann-Whitney U test. 
Relationship between continuous variables that were not 
normally distributed and collateral grade was tested with 
Spearman correlation test. History of stable angina pectoris and 
serum MPO level were found to be significantly correlated with 
collateral grade. Therefore, these variables were used in a 
multiple logistic regression analysis as independent variables to 
determine their effect on collateral grade. Statistical significance 
was defined as p<0.05. The SPSS statistical software (SPSS for 
windows 11.5, SPSS Inc, Chicago, IL) was used for all statistical 
calculations.
Results
Clinical characteristics of the population
The patient population consisted of 218 males (74%) and 77 
females (26%) (mean age, 63±10 years). The prevalence of 
various demographic, angiographic and therapy related 
characteristics of the study subjects at the time of coronary 
angiography according to collateral classification are shown in 
Table 1. Of the 295 patients, 169 had good collaterals (grade 3 and 
grade 2), whereas 126 had poor collaterals (grade 1 and grade 0). 
Subjects with good collaterals were significantly more likely to 
have stable angina pectoris history (p=0.025) and the prevalance 
of RCA (right coronary artery) lesion was higher in the good 
collateral group (p=0.02) whereas CX (circumflex artery) lesion 
was higher in the poor collateral group (p<0.0001). The 
prevalence of all other cardiovascular risk factors and use of 
medications were similar at different levels of collaterals.
The relationship of collateral grade and TNF-alpha, MPO 
and hsCRP
TNF-alpha, MPO, hsCRP levels, white blood cell counts and 
subgroup levels were shown in Table 2. hsCRP, TNF-alpha levels, 
white blood cell counts and subgroup levels were not significantly 
different among groups (p>0.05) (Table 2). Furthermore MPO 
levels were significantly higher in the good collateral group than 
poor collateral group (3.7 U/mL vs. 3.0 U/mL, p=0.001) (Table 2, 
Fig. 1). We also found very weak correlation between the MPO 
levels and collateral grade albeit p value was significant 
(p=0.009, r=0.15) (Fig. 2). In multiple logistic regression analysis, 
stable angina pectoris [odds ratio 1.7, 95% confidence interval 
(1.05-2.8), p=0.03] and high MPO levels [odds ratio 2.7, 95% 
confidence interval (1.7-4.3), p<0.001] were found to be 
independent predictors of good collateral development (Table 3).
  Group 1 Group 2 *P 
  (n=169) (n=126) value
Mean age, years  63±10.6 63±10.2 0.996
Gender (M/F), n  127/42 91/35 0.571
Hypertension, n (%)  124 (73.4) 91 (72.2) 0.826
Diabetes mellitus, n (%)  64 (37.9) 48 (38.1) 0.969
Smoking, n (%)  62 (36.7) 44 (34.9) 0.755
Hyperlipidemia, n (%)  84 (49.7) 59 (46.8) 0.625
Family history of CAD, n (%) 65 (38.5) 56 (44.4) 0.301
Previous MI, n (%)  76 (45) 57 (45.2) 0.964
History of stable angina pectoris, n (%) 104 (61.5) 61 (48.4) 0.025
Occluded coronary LAD, n (%) 38 (22.5) 36 (28.6) 0.233
artery Cx, n (%) 15 (8.9) 30 (23.8) <0.0001
 RCA, n (%) 120 (71.0) 60 (47.6) <0.0001
Beta-blockers, n (%)  120 (71) 91 (72.2) 0.819
ACE-Is or ARBs, n (%)  138 (81.7) 93 (73.8) 0.106
Nitrates, n (%)  91 (53.8) 70 (55.6) 0.771
Aspirin, n (%)  164 (97.0) 125 (99.2) 0.193
Statins, n (%)  126 (74.6) 103 (81.7) 0.143
LDL, mg/dL   107.5±39.7 107±36.8 0.912
Total cholesterol, mg/dL  178±45.5 181.5±45.8 0.515
HDL, mg/dL  41.1±26.7 40.2±12.2 0.719
Triglycerides, mg/dL   153.6±80.4 171.2±115.6 0.328
Fasting glucose, mg/dL  120.6±60.5 124.5±66.9 0.979
Data are presented as number (percentage) and mean±SD values 
Group 1; good collateral, Group 2; poor collateral 
* Student-t test and Mann-Whitney U test 
ACE-I - angiotension converting enzyme inhibitor; ARB - angiotension receptor blocker;  
CAD - coronary artery disease; Cx - circumflex artery; F - female; Gender- Male/Female 
HDL - high density lipoprotein; LAD - left anterior descending artery; LDL - low density 
lipoprotein; MI - myocardial infarction M/F; RCA - right coronary artery; SD - standard deviation
Table 1. Characteristics of the subjects according to collateral groups
 Group 1 (n=169) Group 2 (n=126) 
 mean±SD mean±SD *P
TNF-alpha, pg/mL 37.9±117.2 25.8±47.4 0.940
MPO, U/mL 3.7±2.0 3.0±2.0 0.001*
hsCRP, mg/L 13.7±19.5 13.7±21.2 0.990
WBC, x109cells/L 8400±3000 8500±2700 0.622
Neutrophils, % 64.9±11.2 63.4±9.6 0.235
Lymphocytes, % 24.4±9.4 24.5±7.9 0.873
Monocytes, % 8.0±2.7 7.8±2.5 0.438
*significant 
*Student-t test and Mann-Whitney U test 
HsCRP - high sensitive C-reactive protein; MPO - myeloperoxidase; SD - standard 
deviation; TNF-alpha - tumor necrosis factor alpha; WBC - white blood cell
Table 2. Relationship between inflammatory markers and collateral 
growth
 *P value OR CI 95%
History of stable angina pectoris 0.03 1.7 1.05-2.8
MPO, >2.91 U/mL <0.001 2.7 1.7-4.3
*Multiple logistic regression analysis 
Dependent variable collateral grade, independent variables-history of stable angina 
pectoris, serum MPO level 
MPO - myeloperoxidase
Table 3. Predictors of good collateral arteries
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Discussion
In this study, we aimed to indentify possible determinants of 
coronary collaterals in patients with severe coronary artery 
disease. We found that stable angina pectoris and MPO levels 
were independent predictors of development of coronary 
collaterals.
The presence of collateral vessels protects the heart from 
myocardial ischemia and infarction, and following an infarction 
by enabling the development of less Q wave MI, left ventricular 
aneurysm and coronary failure. So they provide a positive effect 
in in-hospital and long-term prognosis (1). An increased shear 
stress following serious arterial blockage arteriogenesis is 
stimulated. In this mechanism it is thought that MCP-1 (monocyte 
chemotactic protein-1) is effective. While shear stress is at a 
maximum at the beginning, this stress gradually decreases as 
the diameter of collateral arteries expands (5, 7, 8). Assuming 
that hypertension plays a facilitating role in this mechanism, we 
can consider it to have a positive effect on collateral development. 
In our study, hypertension in the good collateral group was also 
detected more but this difference was not found to be statistically 
significant.
We know that coronary collateral growth is impaired in type 2 
diabetes mellitus and metabolic syndrome (24). In our study, 112 
diabetic patients were present and in terms of DM frequency, no 
significant difference was determined among the two groups. 
This may due to insufficient number of patients and undetectable 
arteries formed by angiogenesis with coronary angiography. 
Additionally, a comparison of the number of diseased arteries 
between the two groups was not carried out in this study.
Although many studies have suggested that statins and 
nitrates may promote vessel growth, clinical study results are 
generally lacking (8, 25). We did not find any relation between 
coronary colllateral and use of this group of drugs.
In the latest studies conducted, it has been suggest that CRP 
results in differentiating endothelial precursor cells, that it badly 
effects survival and that it disrupts the angiogenic and 
arteriogenic functions of the cells (15, 18). Whereas in the study 
carried out by Turu et al. (16) CRP stimulated in angiogenesis. 
Even though there are studies that show an inverse relationship 
between collateral artery development and high CRP levels (15), 
we did not determine a meaningful relationship between 
collateral development and hsCRP in our study.
Barron et al. (26) in a study conducted on 975 patients found 
a correlation between high blood cell counts, increased 
thrombus load, increased coronary failure and incidences of 
death after acute myocardial infarction. Even though there is no 
study available that indicates the relationship between coronary 
collateral development and white cell counts, we compared 
white cell counts between good and bad collateral arteries and 
found no significant difference.
TNF-alfa is an important cytokine that plays a role in 
inflammation. Its effects on the cardiovascular system are 
currently being researched. Numerous studies have shown that 
TNF-alfa reduces eNOS production in various arteries thus 
leading to a decline in NO production (12-14). In a study carried 
out by Luo et al. (10) TNF-alfa through p55 receptors affected 
arteriogenesis in a positive way. In our study we considered 
TNF-alfa having an effect on angiogenesis. So we compared 
TNF-alfa levels with patients that have good and bad collateral 
but could not determine a significant difference.
Carrão et al. (27) found that granulocyte-colony stimulating 
factor (G-CSF) directly stimulates cardiomyocytes and promote 
angiogenesis. Besides this, there are many studies that indicate 
the important role played by monocytes and macrophages in 
collateral development where MPO is stored (20, 21, 28). 
Kocaman et al. (29) divided 210 patients, where coronary artery 
Figure 2. Correlation between myeloperoxidase level and collateral grade
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stenosis of these patients was 95% or above and did not have 
diabetes, into two groups of good and bad collateral and found 
that the group with good collateral had a high monocyte count 
and that the monocyte count was an independent predictor in 
the development of good collateral. In our study it was 
determined that while in terms of white cell count, a noticeable 
difference was not found among the two groups, the MPO level 
was found to be high among patients with good collateral and 
that this difference was statistically meaningful. We interpreted 
the high level of MPO in particular as due to the possibility of an 
increase in MPO activity in neutrophiles and monocytes. And 
G-CSF may also increase MPO activity but in our study we did 
not measure the serum G-CSF level. Additionally, after a multiple 
logistic regression analysis is carried out, a high MPO level was 
determined to be the independent predictor of good collateral 
artery development. Even though there are no head to head 
studies that show the relationship between collateral 
development and MPO levels in the literature, we consider that 
in collateral development rather than inflammatory cells, the 
proinflammatory enzymes and cytokines secreted from these 
cells can play a more important role.
Study limitations
We consider that low number of subject and unknown 
duration of the medication were the two limitations of this study. 
That’s why having diabetes mellitus and use of medication were 
not significantly different among groups. Additionally we 
performed all measurements at one point in time. HsCRP, MPO, 
blood cell count and TNF-alpha are inflammatory markers and 
we tried to find out the predictive value of them measured at one 
point in time to detect the relation of the presence of collateral 
circulation. Design of our study reflected routine daily practice 
in the majority of cardiology clinics. Repeated angiography 
assesments may be needed but due to the invasive nature of 
coronary angiography we did not perform.
Conclusion
The findings from our study leave us to think that while TNF-
alfa, hsCRP and white cell count does not have a meaningful 
effect on collateral development, MPO levels has a positive 
effect on collateral development. But randomized clinical studies 
with follow up are required to evaluate the role of them on 
cardiovascular outcomes.
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